Figures & data
Figure 1. Percent changes in mean arterial blood pressure in hypertensive group (open circles, n = 7) and nonhypertensive group (closed squares, n = 8) patients undergoing hemodialysis. *p<0.01 hypertensive group vs. nonhypertensive group.
Figure 2. Effects of recombinant human erythropoietin administration on plasma endothelin-1 levels in (□) hypertensive group (n = 7) and (▪) non-hypertensive group (n = 8) hemodialysis patients. Each column represents the mean ± SE. ET: endothelin.
Figure 3. Effects of recombinant human erythropoietin administration on plasma nitric oxide levels in (□) hypertensive group (n = 7) and (▪) nonhypertensive group (n = 8) hemodialysis patients. Each column represents the mean ± SE. NOx: nitric oxide product.
Figure 4. Relation of changes in plasma endothelin-1 (A) or plasma nitric oxide (B) to changes in mean arterial blood pressure. Neither changes in plasma endothelin-1 levels (p = 0.154) nor changes in plasma nitric oxide product levels (p = 0.21) are related significantly to changes in mean arterial blood pressure. ET-1: endothelin-1, NOx: nitric acid product.
Figure 5. Correlation between changes in plasma endothelin/nitric oxide product ratio and changes in mean arterial blood pressure in erythropoietin-induced hypertension. The relative change in mean arterial blood pressure after recombinant human erythropoietin administration was significantly related (p<0.05) to the relative change in plasma endothelin/nitric oxide ratio.
